Telaprevir-Related Dermatitis,Neuroleptic Malignant Syndrome With Risperidone Long-Acting Injection,Tigecycline-Related Pancreatitis,Venlafaxine-Related Psychosis,Neurologic Adverse Effects of Ranolazine

摘要

TELAPREVIR-RELATED DERMATITIS A study was undertaken to evaluate the incidence, type, and severity of telaprevir-associated skin reactions. Skin manifestations have previously been reported in association with pegylated interferon and ribavirin treatment of hepatitis C virus (HCV). Up to 30% of patients experience a usually pruritic dermatitis or eczematiform skin eruption. The eruptions are most often mild or moderate and seldom lead to the discontinuation of treatment. When the HCV protease inhibitor telaprevir is added to pegylated interferon and ribavirin therapy, it significantly increases the rate of sustained viral response in patients with genotype 1 chronic HCV infection.The authors, who were dermatologists, reviewed data from phase 1 to 3 studies of telaprevir in combination with interferon and ribavirin, which included a total of 2,290 patients. The authors assessed available information including photographs, biopsy results, and clinical summaries of all cases with skin eruptions reported as moderate or severe during the telaprevir clinical development program. In their review, adverse skin events occurred significantly more frequently with telaprevir plus peginterferon and ribavirin {56%) as compared to placebo plus peginterferon and ribavirin (34%). In addition, severe skin